-
Clin Cancer Res: PATRICIA Trials . . Palbociclib co-curtoju single anti-treatment HER2 positive advanced breast cancer
Time of Update: 2020-11-25
The ability of curto-pearl monoantigen, pato-pearl monoantigen and T-DM1 significantly improved the survival prognostic period of advanced HER2-positive breast cancer.
PATRICIA study is a forward-looking, open-label, multi-center Phase II trial designed to assess the efficacy and safety of Palbociclib-co-or-not-combination endocrine therapy in patients with HER2-positive advanced breast cancer.
-
Nat Commun: The Team at Peking University, in association with the U.S. National Cancer Institute, found that FAM3D is a necessary condition for protecting against inflammation-causing tumors
Time of Update: 2020-11-25
Recently, researchers in China have documented that the absence of Fam3D is associated with impaired integrity of the colon mucous membranes, increased epithelial growth, reduced production of antimicrobial peptides, and increased sensitivity to chemically induced colitis, and is associated with a high incidence of cancer.
-
Br J Cancer: Prospective cohort study of serum lipid mass spectrometry and colorectal cancer risk
Time of Update: 2020-11-25
Blood lipid levels were compared to the risk of colorectal cancer, and the results showed that blood lipid levels were not associated with the risk of colorectal cancer when the obesity indicators were adjusted, while the potential site-specific effects of triglycerides and lipoprotein A needed further confirmation.
-
Nat Biotechnol: Ten years of monitoring have found that AAV, the safest gene therapy vector, has potential carcinogenicity
Time of Update: 2020-11-25
The study's AAV virus gene therapy trial on dogs with type A haemophilia was effective, and after a decade of observation after treatment, the team found that some of the therapeutic gene fragments carried by the AAV virus were integrated into the dog's chromosomes to control growth, with the possibility of cancer.
-
Br J Cancer: The new CD63-BCAR4 fusion protein promotes tumor-causing and metastasis of lung adenocarcinoma
Time of Update: 2020-11-25
based on RNA sequencing data analysis, the researchers identified a fusion transcript of CD63-BCAR4 in a Korean lung adenocarcinoma patient who did not carry a known activation mutation of the EGFR and KRAS genes, and studied the carcinogenic effects of CD63-BCAR4 in further experiments.
-
Nature Communications: New research could help predict who is more likely to develop cancer
Time of Update: 2020-11-25
results provide new insights into how HR can be activated through an unusual mechanism in BPDE compounds and processes, even without stagnating or folding replication forks: it is activated at single-stranded gaps in DNA that are caused by the Reboot activity of the PrimPol gene.
-
NEJM: For advanced ALK-positive lung cancer: Lara tinib or clotinib
Time of Update: 2020-11-25
CROWN trial is a global randomized Phase 3 trial that compares the conditions of Lara tinib and closinib (both treated with standard first-line treatment at the beginning of the trial) in patients with advanced ALK-positive NSCLC who had not previously been treated.
-
NEJM: "Head-to-head" Phase III studies have confirmed the treatment of ALK-positive non-small cell lung cancer, and loratinib is significantly superior to closinib
Time of Update: 2020-11-25
results showed that the Lorbrena treatment group had 78 percent of patients who survived without disease progress at 12 months, compared with 39 percent in the Xalkori group, and that Lorbrena reduced the risk of disease progress or death by 72 percent compared to Xalkori, reaching the main end of PFS.
-
Nat Commun: Significant progress! Wang Xiaojian/Cai Xiujun of Zhejiang University has discovered a new prognostode marker for colorectal cancer
Time of Update: 2020-11-25
study found that cytostic IRF3 in a stationary state inhibits the occurrence of colorectal tumors by blocking the transmission of the Wnt/β-catenin signal.
, the study found that cytostic IRF3, which is still, inhibits the occurrence of colorectal tumors by blocking the transmission of the Wnt/β-catenin signal.
-
Sci Adv: RISPR gene editing successfully treats cancer in live animals and is permanently effective
Time of Update: 2020-11-25
In this study, the team reported on the development of targeted non-viral lipid nanoparticles (LNP) delivery systems for therapeutic genome editing and evaluated them in two invasive and incurable cancer models, glioblastoma and ovarian cancer.
-
JAHA: Heart toxicity and cardiovascular biomarkers in breast cancer patients
Time of Update: 2020-11-25
results, NT-proBNP and hemoglobin were significantly associated with cardiac toxicity in patients with early stage breast cancer who received dose-enhanced chemotherapy, whereas hypersensitive heart ticklein T was not.
-
JASN: Childhood Cancer and ESKD Risk
Time of Update: 2020-11-25
after obtaining detailed historical data, the researchers divided the queue into three groups: subjects with no tumor history, a history of benign tumors (non-malignant tumors with impaired function), and a history of malignant tumors (excluding kidney cancer).
-
Cells: Immune cells for tumors can be found in just 1 day!
Time of Update: 2020-11-11
The simple way to detect and isolate immune cells that respond to tumors can be treated by created more of these cells outside the patient's body and re-delivered back to the patient," said Professor Peng Wu, lead author of the study.
-
Nature Medicine interpretation! How does melanoma trick the host body's immune system into increasing its tolerance to chemotherapy?
Time of Update: 2020-11-10
October 27, 2020 // -- Complex human immune systems have evolved into an effective protective system against a variety of diseases, such as cancer, and the immune system can use a monitoring process c
-
Multiple articles explain the mysterious link between Helicobacterrobacteria and stomach cancer!
Time of Update: 2020-11-09
In a recent study published in the international journal Science Advances, scientists from the University of California developed a new method by which researchers identified a special protein molecular structure that promotes helicobacter pyridoxine survival in the stomach, and the researchers explained the mechanism by which this particular protein worked.
-
Diagnosis and treatment of GBM soft meninges
Time of Update: 2020-11-09
The results showed that GBM cells migrated from the initial position of the tumor along the soft membrane of cerebrovascular vessels, under the cobweb membrane and under the chamber membrane (Figure 1).
-
Multiple articles focus on scientists' new findings in cancer biomarker research!
Time of Update: 2020-11-09
article, we've compiled a number of achievements that scientists have made in recent years in the study of cancer biomarkers, and learn from them! Photo credit: Dr. Cecil Fox, National Cancer Institu
-
Roche Taishengqi® immune combination therapy program approved in China for the treatment of hepatocellular carcinoma
Time of Update: 2020-11-09
On October 28, 2020, Roche announced that China's State Drug Administration (NMPA) had approved its cancer immuno-innovative drug Atiliju monoanti (trade name: Tai Sanqi ®, Tecentriq®) to treat patients with non-excisible hepatocellular carcinoma (HCC) who had not previously received systematic treatment.
-
The application ratio of 3D high-definition and 2D-4K ultra-high-definition endoscopic systems in trans-nose subcranial surgery
Time of Update: 2020-11-08
Yoichi Uozumi of Neurosurgery, Kobe University School of Medicine, Japan, and others analyzed the differences in characteristics between 3D-high-definition and 2D-4K ultra-high-definition endoscopy systems, as well as their respective advantages in clinical surgery, and compared them with conventional 2D standard-definition endoscopy systems, and published the results in the September 2020 issue of the journal Operation Neurosurgery.
-
HER2-positive stomach cancer first ADC drug! AstraZeneta/13 Enhertu USA Priority Review: Redefining Gastric Cancer Treatment!
Time of Update: 2020-11-08
Enhertu received the world's first batch in december 2019 in the United States: FDA Accelerated Approval for ADULT patients with HER2-positive metastasis breast cancer who have received 2 or more anti-HER2 drugs in metastasis diseases.
